The detection and accurate classification of PVs in BRCA2, among other hereditary cancer genes, proffers a notable benefit to carriers of disease-causing variants and their biological family members found to carry the same PVs who can benefit from enhanced cancer surveillance for the early detection of hereditary cancer and/or pursue prophylactic measures to aid in the prevention of certain cancers. This evidence concerns the gene BRCA2 and cancer.